Lecture 14 - Antifungals Flashcards
Eukaryotic - ______
mycoses
Cell membrane contains _______
ergosterol
Cell wall; ____ is a polymer of N-acetylglucosamine
chitin
Describe how Amphotericin B is used in “Subcutaneous and systemic mycotic infections”
- Polyene macrolide
- Produced by Streptomyces nodosus
- For life threatening disease
- Binds to ergosterol - not cholesterol
- Forms pores
- Wide range of fungi
- Candida and blastomyces
- Used against aspergillum and protozoa (leishmaniasis)
- 1st line therapy and then substituted
Describe the pharmacokinetics of Amphotericin B
- poorly absorbed from GI tract, intravenous
- insoluble in water
- intrathecal for meningitis
- delivered in liposomes - lower toxicity
Adverse effects of Amphotericin B
- low therapeutic index
- daily dose < 1.5 mg/kg
Effects that may happen after the initial infusion of amphotericin B?
- anaphylaxis and convulsions
- fever
- hypotension
Effects that may happen after a longer term treatment of Amphotericin B?
- renal impairment
- anemia
- neurological effects
- thrombophlebitis (blood clot formation)
Describe Flucytosine (5-FC)
- synthetic pyrimidine antimetabolite
- enters via specific cytosine permeate - not in mammals
- converted to 5’-fluorodeoxyuridine monophosphate (5-FdUMP)
- false nucleotide inhibits thymidylate synthase
- blocks thymidylic acid - needed for DNA
- synergy with amphotericin B
- limited spectrum (candida and some molds)
Resistance to Flucytosine
Target enzyme can be down-regulated and lead to resistance - need for combination therapy
Pharmacokinetics of Flucytosine
- water soluble
- good BBB passage
Adverse effects of flucytosine ?
- neutropenia (low neutrophil number)
- bone marrow depression
- nausea, vomiting
- contraindicated with renal impairment
Toxic metabolite of flucytosine?
fluorouracil
Describe posaconazole
- synthetic triazole for systemic fungi infection
- inhibits C-14 alpha demethylase (cyt P450 enzyme)
- blocks demethylation of lanosterol to ergosterol
- disrupts membrane structure/function
- oral with high absorption
- more specific than previous azoles (itraconazole) and imidazole (ketoconazole)
- wide fungi range - species of Candida and Aspergillus
- Resistance becoming a problem in HIV patients
Pharmacokinetics of Posaconazole
- oral: gastric acid needed
- major binding to plasma proteins
- metabolized by liver
- poor CNS penetration
Adverse effects of Posaconazole
minor GI upset
Drug interactions with Posaconazole
Inhibition of Cyt P450 (rifampin an inducer)
Describe Caspofungin
- new group of fungicides
- echinocandins
- inhibit B-1,3-D-glycan
- cell wall disruption and death
- Aspergillus and candida
- T1/2 of 9-11 hour
- 2nd line therapy
Drugs for cutaneous mycotic infections (dermatophytes - ringworm)
Terbinafine:
- Inhibit squalene epoxidase and blocks ergosterol
- Squalene build-up is toxic
- 3 month therapy
- Oral; 40% bioavailability
- Accumulates in breast milk
- Gastrointestinal disturbance
Problem with treating eukaryotes with antiprotozoal drugs?
metabolism close to humans
Toxicity issues with antiprotozoal drugs?
especially toxic against metabolically active cells (ex. neurons, stem cells)
Can pregnant patients be treated with antiprotozoal drugs?
no
Describe amebiasis - amebic dysentery
- Entamoeba histolytica
- Anaerobic protozoan
- 50 million infected
- Causes fulminating diarrhea
- Liver abscess
- Can be dormant
Describe the life cycle of E. histolytica
- Cysts: survive outside the body
- Trophozoites
- Ulcerate intestine
- Feed off and kill host bacteria